U.S. License Holder:
Ultragenyx Pharmaceutical Inc.
Date of License:
CRYSVITA (burosumab-twza) is a fibroblast growth factor 23 (FGF23) blocking antibody indicated for:
The treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older;
The treatment of FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localizedin adult and pediatric patients 2 years of age and older.